February 2024 – Ashvattha Therapeutics

Ashvattha Therapeutics Announces First Patient Enrolled in Expanded Phase 1/2 Study of Imaging Agent 18F-OP-801 in Additional Neurological Indications

February 22, 2024 by Walid

The study will evaluate the safety, tolerability, and ability of 18F-OP-801 to cross the blood-brain barrier and selectively target neuroinflammation in individuals with amyotrophic lateral sclerosis, Alzheimer’s disease, multiple sclerosis and Parkinson’s disease Preliminary data expected in 1H 2024 REDWOOD CITY, Calif., February 22, 2024 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new … Read more

Ashvattha Therapeutics to Participate in Upcoming Investor Conferences

February 14, 2024 by Dan Hennings

REDWOOD CITY, Calif., February 14, 2024 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that members of its senior management team will participate in two upcoming investor conferences. Conference Details: BIO CEO & Investor Conference … Read more